Our future approach to determining whether cancer-derived FGF2 is critical in tumor progression is to use knockout mice with either prostate-specific or whole-mouse deletion of FGF2 to determine whether prostate cancer progression in transgenic mouse models is affected. This evidence concerns the gene FGF2 and neoplasm.